^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
JS201
i
Other names: JS201
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Shanghai Junshi Biosci
Drug class:
PD1 inhibitor, TGFβ inhibitor
Related drugs:
3ms
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer (clinicaltrials.gov)
P2, N=30, Recruiting, Hunan Province Tumor Hospital | Trial primary completion date: Jun 2024 --> Dec 2024
Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Lenvima (lenvatinib) • JS201
12ms
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer (clinicaltrials.gov)
P2, N=30, Recruiting, Hunan Province Tumor Hospital | Trial completion date: Jun 2023 --> Jun 2025 | Trial primary completion date: Jun 2022 --> Jun 2024
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Lenvima (lenvatinib) • JS201
over3years
Clinical Study of JS201 in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
P1, N=174, Recruiting, Shanghai Junshi Bioscience Co., Ltd.
Clinical • New P1 trial
|
PD-1 (Programmed cell death 1) • TGFB1 (Transforming Growth Factor Beta 1)
|
JS201
over3years
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer (clinicaltrials.gov)
P2, N=30, Recruiting, Hunan Province Tumor Hospital
Clinical • New P2 trial
|
PD-L1 (Programmed death ligand 1)
|
Lenvima (lenvatinib) • JS201
Share via
